Navigation Links
Aratana Therapeutics Adds to Commercial Leadership Team
Date:10/24/2013

es for the foreseeable future; our lack of commercial sales; our failure to obtain any necessary additional financing; our substantial dependence on the success of our current compounds, AT-001, AT-002 and AT-003, which are still in development; our inability to identify, license, develop and commercialize additional product candidates; our inability  to obtain regulatory approval for our existing or future product candidates;  the lack of commercial success of our current or future product candidates; uncertainties regarding the outcomes of studies regarding our products; effects of competition; our failure to attract and keep senior management and key scientific personnel; our complete reliance on third-party manufacturers and third parties to conduct all our target animal studies and certain other development efforts; our lack of a sales organization; our significant costs of operating as a public company; our lack of effective internal control over financial reporting; changes in distribution channels for pet therapeutics; consolidation of our customers; impacts of generic products; unanticipated safety or efficacy concerns; our limited patents and patent rights; our failure to comply with our intellectual property license obligations; our infringement of third party patents and challenges to our patents or rights; our failure to comply with regulatory requirements; our failure to report adverse medical events related to our products; legislative or regulatory changes; the volatility of our stock price; our status as an "emerging growth company," as defined in the JOBS Act; the potential for dilution if we sell shares of our common stock in future financings; the significant control over our business by our principal stockholders and management; the potential that a significant portion of our total outstanding shares could be sold into the market in the near future; effects of anti-takeover provisions in our charter documents and under Dela
'/>"/>
SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Aratana Therapeutics names Wendy Yarno to its Board of Directors
2. Aratana Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
3. Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
4. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
5. Aratana Therapeutics Reports Second Quarter 2013 Financial Results
6. Aratana Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
7. Aratana Therapeutics to Present at Two Upcoming Healthcare Conferences
8. Aratana Closes $12 Million Series C Financing to Fund Pipeline Expansion
9. Aratana Therapeutics Appoints Erick Lucera Vice President of Corporate Development
10. Aratana to Present at Bank of America Merrill Lynch Animal Health Summit
11. Aratana to Participate in Leerink Swanns November Management Access Days
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... BIRMINGHAM, Ala. , Jan. 23, 2015 Gem ... (STS) patients have been enrolled into the Company,s Phase ... efficacy and safety of Gem,s lead compound, GPX-150 (an ... for advanced or metastatic disease. Logo - ...
(Date:1/22/2015)... UPI ), a medical device company that develops, manufactures ... today reported financial results for the fiscal 2015 third ... the Company,s Urgent ®  PC Neuromodulation System grew 14.5% ... compared to $3.9 million in the third quarter of ...
(Date:1/22/2015)... SAN DIEGO , Jan. 22, 2015  Profil Institute ... focused on diabetes and obesity, announced today a new ... Drug Development,  published by Springer, a leading global scientific ... extensively analyze and illustrate techniques for use in early ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... , NEW YORK, Nov. 19 ... Model: Science or Swag?" , Who: W. Scott ... , Where: www.deloitte.com/us/debates/scienceorswag ... best way to sell their products. Even if they could find ...
... , ALLEGAN, Mich., Nov. 19 Perrigo Company (Nasdaq: ... Joseph C. Papa will present at the Sidoti Emerging Growth ... the Grand Hyatt Hotel in New York City. ... develops, manufactures and distributes OTC and prescription pharmaceuticals, nutritional products, ...
Cached Medicine Technology:Time to Blow Up the Pharmaceutical Sales Model? New Deloitte Debate 2Time to Blow Up the Pharmaceutical Sales Model? New Deloitte Debate 3
(Date:1/22/2015)... New York, New York (PRWEB) January 22, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) in the U.S. District Court, Southern District ... against C.R. Bard, Inc. in that proceeding’s first bellwether trial. ... defense request for a new trial after finding that C.R. ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... January 22, 2015 Autocarinsurancebest.com has released a ... a commercial auto insurance policy . , Auto insurance ... vehicles. It is no longer necessary to call an agent ... now available online on a single website: http://autocarinsurancebest.com/ . ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post presenting ... . , Purchasing an accidental death and dismemberment rider ... type of rider provides benefits if the insured dies in ... lesser form of life insurance. , AD&D is not ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 ... of Sports Medicine flagship journal Medicine & Science ... L-Citrulline before exercise may help reduce gastrointestinal (GI) ... 1 , Participants in the double-blind, placebo-controlled ...
Breaking Medicine News(10 mins):Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3
... Support NIH Information Sharing and Collaboration ServicesCHANTILLY, Va., ... region,s leading providers of government professional technical solutions, ... by the National Institutes of Health (NIH) for ... February 18, 2009, covers a one year period ...
... 25 AdaptaVan, LLC has announced partnerships with ... of its customized wheelchair-accessible vans throughout ... Emmett Koelsch Coaches, Inc. of Oregon City, Ore.; ... Conn.; Superior Chevrolet, Inc. of Cincinnati, Ohio; Autotronics ...
... Cancer Center have developed an assay that may be ... a predisposition to cancer. , The study, published in ... done in yeast and mammalian cells. , Cancer cells ... Robert Schiestl, have discovered a mechanism that switches on ...
... LONDON, March 25 Clinica - the world,s leading medical,technology ... state of,asbestos regulation in the UK, in light of discrepancies ... Westminster. , On the day of ... latest developments in Clinica,s investigation into the extent,of the problem ...
... March 25 Abbott ( NYSE: ABT ) will announce ... before the market opens.The announcement will be followed by a ... Central time (9 a.m. Eastern), and will be accessible through ... An archived edition of the call will be available after ...
... Physicians Practice and Rose Medical Center have joined forces ... time to devote to patient care. This new partnership ... the Denver Metro Area better handle the cumbersome and ... new alliance, Rose Medical Center will use Physicians Practice,s ...
Cached Medicine News:Health News:NIH Awards Blanket Purchase Agreement (BPA) to Citizant 2Health News:AdaptaVan, LLC Expands National Availability of Wheelchair-Accessible Vans 2Health News:Discovery may result in new test to determine predisposition to cancer 2Health News:Discovery may result in new test to determine predisposition to cancer 3Health News:Westminster Safety Disagreement Highlights Risk in Schools 2Health News:Westminster Safety Disagreement Highlights Risk in Schools 3Health News:Physicians Practice and Rose Medical Center Partner to Improve Patient Care in the Denver Metro Area 2Health News:Physicians Practice and Rose Medical Center Partner to Improve Patient Care in the Denver Metro Area 3
Maumenee tying forceps is straight with concave-convex jaws and has a round handle with guide pin. For 8-0 to 11-0 sutures....
Jaffe tying forceps is very delicate with smooth jaws, straight, 6 mm long platform. For 8-0 to 11-0 sutures....
Sinskey tying forcep is very delicate with smooth jaws, curved. For 8-0 to 11-0 sutures....
McPherson titanium tying forceps which is 5 mm long, smooth jaws and straight. Used for 8-0 to 11-0 sutures....
Medicine Products: